Neutron or photon irradiation for prostate tumors

Enhancement of cytokine therapy in a metastatic tumor model

G. G. Hillman, R. L. Maughan, David Grignon, M. Yudelev, J. Rubio, S. Tekyi-Mensah, A. Layer, M. Che, J. D. Forman

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We have shown that implantation of human prostate carcinoma PC-3 cells in the prostates of nude mice led to the formation of prostate tumors with metastases to para-aortic lymph nodes. We found that day 6 prostate tumors were responsive to systemic injections of interleukin 2 (IL-2) therapy. We have now investigated the combination of primary tumor irradiation and IL-2 for metastatic prostate cancer in this preclinical tumor model. The effect of neutron radiation was compared with that of photon radiation. Advanced prostate tumors (∼0.4 cm) were irradiated, and a day later, mice were treated with systemic IL-2 for three weekly cycles. In separate experiments, mice were either sacrificed on day 30 to assess prostate tumor size and tumor histology or followed for survival. A dose-dependent inhibition of prostate tumor growth was caused either by photons or neutrons, but neutrons were more effective than photons with a relative biological effectiveness of 2. The tumor inhibition obtained with 250 cGy neutrons and 500 cGy photons was significant (>75%) and was further increased (≥90%) by addition of IL-2 therapy. In survival studies, the combination of radiation and IL-2 showed a significant survival advantage compared with untreated mice (P ≤ 0.005) or radiation alone (P ≤ 0.003) and an increase in median survival compared with IL-2 alone. Histologically, the combined regimen resulted in a greater degree of tumor destruction, inflammatory response, and vascular damage than that observed with each modality alone. After this combined treatment, no tumor was histologically detected in the para-aortic lymph nodes of these mice, and the lymph nodes were significantly smaller. These findings showed that primary tumor irradiation, either with neutrons or photons, enhanced IL-2 therapeutic effect for the treatment of advanced prostate cancer. This combined modality induced an antitumor response that controlled the growth of prostate tumors and their metastases.

Original languageEnglish (US)
Pages (from-to)136-144
Number of pages9
JournalClinical Cancer Research
Volume7
Issue number1
StatePublished - 2001
Externally publishedYes

Fingerprint

Neutrons
Photons
Prostate
Cytokines
Interleukin-2
Neoplasms
Therapeutics
Survival
Lymph Nodes
Radiation
Prostatic Neoplasms
Relative Biological Effectiveness
Neoplasm Metastasis
Radiation Effects
Therapeutic Uses
Growth
Nude Mice
Blood Vessels
Histology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hillman, G. G., Maughan, R. L., Grignon, D., Yudelev, M., Rubio, J., Tekyi-Mensah, S., ... Forman, J. D. (2001). Neutron or photon irradiation for prostate tumors: Enhancement of cytokine therapy in a metastatic tumor model. Clinical Cancer Research, 7(1), 136-144.

Neutron or photon irradiation for prostate tumors : Enhancement of cytokine therapy in a metastatic tumor model. / Hillman, G. G.; Maughan, R. L.; Grignon, David; Yudelev, M.; Rubio, J.; Tekyi-Mensah, S.; Layer, A.; Che, M.; Forman, J. D.

In: Clinical Cancer Research, Vol. 7, No. 1, 2001, p. 136-144.

Research output: Contribution to journalArticle

Hillman, GG, Maughan, RL, Grignon, D, Yudelev, M, Rubio, J, Tekyi-Mensah, S, Layer, A, Che, M & Forman, JD 2001, 'Neutron or photon irradiation for prostate tumors: Enhancement of cytokine therapy in a metastatic tumor model', Clinical Cancer Research, vol. 7, no. 1, pp. 136-144.
Hillman, G. G. ; Maughan, R. L. ; Grignon, David ; Yudelev, M. ; Rubio, J. ; Tekyi-Mensah, S. ; Layer, A. ; Che, M. ; Forman, J. D. / Neutron or photon irradiation for prostate tumors : Enhancement of cytokine therapy in a metastatic tumor model. In: Clinical Cancer Research. 2001 ; Vol. 7, No. 1. pp. 136-144.
@article{92ee9c0552444163998824c4439858dc,
title = "Neutron or photon irradiation for prostate tumors: Enhancement of cytokine therapy in a metastatic tumor model",
abstract = "We have shown that implantation of human prostate carcinoma PC-3 cells in the prostates of nude mice led to the formation of prostate tumors with metastases to para-aortic lymph nodes. We found that day 6 prostate tumors were responsive to systemic injections of interleukin 2 (IL-2) therapy. We have now investigated the combination of primary tumor irradiation and IL-2 for metastatic prostate cancer in this preclinical tumor model. The effect of neutron radiation was compared with that of photon radiation. Advanced prostate tumors (∼0.4 cm) were irradiated, and a day later, mice were treated with systemic IL-2 for three weekly cycles. In separate experiments, mice were either sacrificed on day 30 to assess prostate tumor size and tumor histology or followed for survival. A dose-dependent inhibition of prostate tumor growth was caused either by photons or neutrons, but neutrons were more effective than photons with a relative biological effectiveness of 2. The tumor inhibition obtained with 250 cGy neutrons and 500 cGy photons was significant (>75{\%}) and was further increased (≥90{\%}) by addition of IL-2 therapy. In survival studies, the combination of radiation and IL-2 showed a significant survival advantage compared with untreated mice (P ≤ 0.005) or radiation alone (P ≤ 0.003) and an increase in median survival compared with IL-2 alone. Histologically, the combined regimen resulted in a greater degree of tumor destruction, inflammatory response, and vascular damage than that observed with each modality alone. After this combined treatment, no tumor was histologically detected in the para-aortic lymph nodes of these mice, and the lymph nodes were significantly smaller. These findings showed that primary tumor irradiation, either with neutrons or photons, enhanced IL-2 therapeutic effect for the treatment of advanced prostate cancer. This combined modality induced an antitumor response that controlled the growth of prostate tumors and their metastases.",
author = "Hillman, {G. G.} and Maughan, {R. L.} and David Grignon and M. Yudelev and J. Rubio and S. Tekyi-Mensah and A. Layer and M. Che and Forman, {J. D.}",
year = "2001",
language = "English (US)",
volume = "7",
pages = "136--144",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Neutron or photon irradiation for prostate tumors

T2 - Enhancement of cytokine therapy in a metastatic tumor model

AU - Hillman, G. G.

AU - Maughan, R. L.

AU - Grignon, David

AU - Yudelev, M.

AU - Rubio, J.

AU - Tekyi-Mensah, S.

AU - Layer, A.

AU - Che, M.

AU - Forman, J. D.

PY - 2001

Y1 - 2001

N2 - We have shown that implantation of human prostate carcinoma PC-3 cells in the prostates of nude mice led to the formation of prostate tumors with metastases to para-aortic lymph nodes. We found that day 6 prostate tumors were responsive to systemic injections of interleukin 2 (IL-2) therapy. We have now investigated the combination of primary tumor irradiation and IL-2 for metastatic prostate cancer in this preclinical tumor model. The effect of neutron radiation was compared with that of photon radiation. Advanced prostate tumors (∼0.4 cm) were irradiated, and a day later, mice were treated with systemic IL-2 for three weekly cycles. In separate experiments, mice were either sacrificed on day 30 to assess prostate tumor size and tumor histology or followed for survival. A dose-dependent inhibition of prostate tumor growth was caused either by photons or neutrons, but neutrons were more effective than photons with a relative biological effectiveness of 2. The tumor inhibition obtained with 250 cGy neutrons and 500 cGy photons was significant (>75%) and was further increased (≥90%) by addition of IL-2 therapy. In survival studies, the combination of radiation and IL-2 showed a significant survival advantage compared with untreated mice (P ≤ 0.005) or radiation alone (P ≤ 0.003) and an increase in median survival compared with IL-2 alone. Histologically, the combined regimen resulted in a greater degree of tumor destruction, inflammatory response, and vascular damage than that observed with each modality alone. After this combined treatment, no tumor was histologically detected in the para-aortic lymph nodes of these mice, and the lymph nodes were significantly smaller. These findings showed that primary tumor irradiation, either with neutrons or photons, enhanced IL-2 therapeutic effect for the treatment of advanced prostate cancer. This combined modality induced an antitumor response that controlled the growth of prostate tumors and their metastases.

AB - We have shown that implantation of human prostate carcinoma PC-3 cells in the prostates of nude mice led to the formation of prostate tumors with metastases to para-aortic lymph nodes. We found that day 6 prostate tumors were responsive to systemic injections of interleukin 2 (IL-2) therapy. We have now investigated the combination of primary tumor irradiation and IL-2 for metastatic prostate cancer in this preclinical tumor model. The effect of neutron radiation was compared with that of photon radiation. Advanced prostate tumors (∼0.4 cm) were irradiated, and a day later, mice were treated with systemic IL-2 for three weekly cycles. In separate experiments, mice were either sacrificed on day 30 to assess prostate tumor size and tumor histology or followed for survival. A dose-dependent inhibition of prostate tumor growth was caused either by photons or neutrons, but neutrons were more effective than photons with a relative biological effectiveness of 2. The tumor inhibition obtained with 250 cGy neutrons and 500 cGy photons was significant (>75%) and was further increased (≥90%) by addition of IL-2 therapy. In survival studies, the combination of radiation and IL-2 showed a significant survival advantage compared with untreated mice (P ≤ 0.005) or radiation alone (P ≤ 0.003) and an increase in median survival compared with IL-2 alone. Histologically, the combined regimen resulted in a greater degree of tumor destruction, inflammatory response, and vascular damage than that observed with each modality alone. After this combined treatment, no tumor was histologically detected in the para-aortic lymph nodes of these mice, and the lymph nodes were significantly smaller. These findings showed that primary tumor irradiation, either with neutrons or photons, enhanced IL-2 therapeutic effect for the treatment of advanced prostate cancer. This combined modality induced an antitumor response that controlled the growth of prostate tumors and their metastases.

UR - http://www.scopus.com/inward/record.url?scp=0035139101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035139101&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 136

EP - 144

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -